Table 1.
Clinical characteristics and disease-specific features of SLE patients.
| Age (years) (Median, range) | 47 (19–80) |
| Disease duration (years) (Mean, SD) | 13.5 (10.1) |
| Antiphospholipid syndrome (N,%) | 10 (13) |
| Antimalarials only (N,%) | 8 (10) |
| Antimalarials + Glucocorticoids (N,%) | 21 (27) |
| Antimalarials + other immunosuppressive therapy (N,%) | 39 (51) |
| No treatment (N,%) | 9 (12) |
| Creatinine (<1.2 mg/dl) (Mean, SD) | 0.8 (0.3) |
| D-dimer (0.1–0.5 μg/ml) (Mean, SD) | 0.69 (2.02) |
| Fibrinogen (150–450 mg/dl) (Mean, SD) | 355 (72) |
| ESR (0–13 mm) (Mean, SD) | 19 (18) |
| hsCRP (0–10 mg/dl) (Mean, SD) | 2.6 (5.3) |
| C3 complement (90.0–180.0 mg/dl) (Mean, SD) | 104 (27) |
| C4 complement (10.0–40.0 mg/dl) (Mean, SD) | 18 (9) |
| Positive ANA (>1:80) (N, %) | 68 (88) |
| Positive anti-dsDNA antibodies (>15 U/ml) (N,%) | 29 (38) |
| IL-6 (0.002–5 ng/ml) (Mean, SD) | 4.42 (4.51) |
| Il-10 (0.002–5 ng/ml) (Mean, SD) | 11 (49.44) |
| TNF (0.002–5 ng/ml) (Mean, SD) | 2.69 (6.76 |
| IFN (0.002–5 ng/ml) (Mean, SD) | 2.26 (2.83) |
| Serological activity (N,%) | 43 (56) |
| SLEDAI-2K (Mean, SD) | 2.2 (2.5) |
| SLEDAI-2K ≥ 4 (N,%) | 21 (27.3) |
| SLICC (Mean, SD) | 1.8 (1.6) |
| SLICC ≥1 (N,%) | 58 (75.3%) |
ESR: Erythrocyte sedimentation rate, hsCRP: High-sensitive C-reactive protein, ANA: Antinuclear antibodies, anti-dsDNA: anti-double-stranded DNA antibody, TNF: Tumor necrosis factor, IFN: Interferon, SLEDAI: SLE Disease Activity Index, SLICC/ACR: Systemic Lupus International Collaborative Clinics/American College of Rheumatology.